Endogenex Receives IDE Approval to Initiate Pivotal Clinical Study

MINNEAPOLIS, Jan. 30, 2024. Endogenex, Inc., a clinical stage medical device company dedicated to improving outcomes in patients with Type 2 Diabetes (T2D), announced that the U.S. Food and Drug Administration (FDA) granted an Investigational Device...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials